Physician profile
Luke Range
NPI 1134665078
$1,032.72
in general payments reported to CMS, 2019-2025
20 companies · $90.58 in 2025
The $90.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $501 · 2024: $255 · 2025: $90.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.85 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $129.80 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $98.45 | 2023-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $97.92 | 2023-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $84.25 | 2022-2023 | |
| Lilly USA, LLC | $64.01 | 2023 | Jardiance, Baqsimi, Lyumjev |
| Amgen INC. | $50.56 | 2022-2023 | Evenity, Prolia |
| Corcept Therapeutics | $34.42 | 2023-2024 | Korlym |
| Exact Sciences Corporation | $31.54 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.88 | 2023 | |
| Xeris Pharmaceuticals, INC. | $30.16 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.43 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $22.46 | 2023 | |
| Amryt Pharma Holdings LTD | $22.13 | 2023 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $19.25 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $17.99 | 2022 | |
| Tandem Diabetes Care, INC. | $16.11 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $13.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.61 | 2024 | Farxiga |
| Beta Bionics, INC. | $12.20 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Range listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.